Hims & Hers Health, Inc. (HIMS) Misses Q2 Earnings and Revenue Estimates

Hims & Hers Health, Inc. (HIMS) reported Q2 EPS of $0.17 and revenue of $544.83 million, missing Zacks consensus estimates by 5.56% and 1.51% respectively. Despite this quarterly miss, the company demonstrated substantial year-over-year growth from $0.06 EPS and $315.65 million in the prior year. HIMS shares have significantly outperformed the S&P 500 year-to-date, gaining 158.7%, and the stock maintains a Zacks Rank #1 (Strong Buy) based on pre-earnings estimate revisions, indicating potential continued outperformance, though future price action will largely depend on management's commentary.

Analysis

Hims & Hers Health, Inc. (HIMS) reported a notable miss on both top and bottom lines for its Q2 2025 results, with earnings per share of $0.17 falling 5.56% short of the $0.18 consensus estimate and revenue of $544.83 million missing by 1.51%. This performance is particularly significant as it breaks a three-quarter streak of revenue beats and marks the third EPS miss in the last four quarters, suggesting potential challenges in forecasting or execution. Despite the miss, the company demonstrated substantial year-over-year growth, with revenue increasing approximately 73% from $315.65 million and EPS growing from $0.06 in the prior-year quarter. This creates a conflicting narrative for a stock that has already appreciated 158.7% year-to-date. While the stock carried a Zacks Rank #1 (Strong Buy) into the report based on a favorable estimate revision trend, the article explicitly cautions that this status may change and that the sustainability of its stock price will depend heavily on management's commentary during the earnings call.

Key Decisions for Investors

• Given the stock's massive year-to-date run-up, the dual miss on earnings and revenue warrants caution, and investors should prioritize analyzing management's upcoming commentary for guidance on future growth and margins.
• The contrast between strong year-over-year growth and the recent miss on consensus estimates requires investors to assess if this is a one-off execution issue or the beginning of a growth deceleration trend before adjusting positions.
• Monitor for any post-earnings revisions to analyst estimates or a change in the company's Zacks Rank, as a downgrade from its current #1 (Strong Buy) status would serve as a key bearish indicator.
• Initiating new long positions carries elevated risk until the market digests the full earnings report and forward guidance, as the stock's high valuation may be vulnerable to a sentiment shift.